Phibro Animal SEC Filings

Phibro Animal Health insider activity shows trades by BFI Co., LLC, an entity associated with President and CEO Jack Bendheim and a 10% owner. On February 4, 2026, BFI converted 30,000 shares of Class B Common Stock into Class A on a one-for-one basis at $0 per share.

BFI then sold Class A shares in several transactions: 6,689 shares at $41.2508, 2,971 shares at $41.9667, and 3,520 shares at $41.1544, all reported as weighted average prices under a Rule 10b5-1 trading plan adopted on May 30, 2025. After these trades, BFI held 48,800 Class A shares indirectly, while Bendheim directly held 16,840 Class A shares and BFI continued to hold additional Class B shares. Bendheim may be deemed to share voting and investment power over BFI’s holdings but disclaims beneficial ownership except for his pecuniary interest.

Phibro Animal Health Corporation filed a Form 8-K stating that on February 4, 2026 it issued a press release announcing operating results for the fiscal quarter ended December 31, 2025 and financial guidance for the fiscal year ending June 30, 2026. The press release is furnished as Exhibit 99.1 and, along with the 8-K disclosure, is designated as "furnished" rather than "filed" under the Securities Exchange Act of 1934, meaning it is not automatically incorporated into other securities law filings unless specifically referenced.

Phibro Animal Health Corporation reported sharply stronger results. For the quarter ended December 31, 2025, net sales reached $373.9 million, up 21% from $309.3 million. Net income rose to $27.5 million from $3.2 million, with basic earnings per share increasing to $0.68 from $0.08.

Growth was led by the Animal Health segment, helped by the October 2024 acquisition of Zoetis’s medicated feed additive and water-soluble products portfolio. This portfolio contributed $94.1 million of quarterly revenue and $174.6 million over six months. Six‑month net sales grew 30% to $737.8 million, while net income climbed to $54.0 million from $10.2 million.

Phibro Animal Health Corporation declared a quarterly cash dividend of $0.12 per share on its Class A and Class B common stock. The dividend will be paid on March 25, 2026 to stockholders who are on record as of the close of business on March 4, 2026.

This cash dividend provides shareholders with a direct cash return based on the number of shares they hold on the record date.

Phibro Animal Health (PAHC) insider activity centers on planned sales by BFI Co., LLC, an entity associated with President and CEO Jack Bendheim. BFI sold 6,772 Class A Common shares at a weighted average price of $40.1192 on January 29, 2026, and 6,693 shares at $40.0941 on January 30, 2026, under a Rule 10b5-1 trading plan adopted on May 30, 2025. After these transactions, BFI held 38,673 and then 31,980 shares indirectly, while Bendheim also directly held 16,840 Class A Common shares.

Phibro Animal Health insider activity shows trades by major shareholder BFI Co., LLC, an entity over which President and CEO Jack Bendheim has voting and dispositive power. On January 23, 2026, BFI sold 1,235 shares of Class A Common Stock at a weighted average price of $40.5538 per share under a Rule 10b5-1 trading plan adopted on May 30, 2025. On January 26, 2026, BFI converted 30,000 shares of Class B Common Stock into Class A Common Stock on a one-for-one basis at an exercise price of $0. Following these transactions, BFI indirectly held 45,445 Class A shares, while Jack Bendheim also directly held 16,840 Class A shares.

Phibro Animal Health’s 10% owner BFI Co., LLC, an entity associated with President and CEO Jack Bendheim, reported planned sales of Class A common stock under a Rule 10b5-1 trading plan adopted on May 30, 2025. On January 21, 2026, BFI sold 14,687 shares at a weighted average price of $41.6782 per share. On January 22, 2026, it sold 11,875 shares at a weighted average price of $41.9086 and 1,283 shares at a weighted average price of $42.6774, with each price reflecting multiple trades within stated ranges. The filing also shows that Jack Bendheim directly held 16,840 Class A shares as of January 21, 2026.

Phibro Animal Health Corp executive Patrick Rodriguez has filed an initial ownership report stating he currently holds no company securities. Rodriguez, who serves as VP Finance and Treasurer, submitted a Form 3 indicating that there are no non-derivative or derivative securities beneficially owned. The filing also notes that the form is filed by one reporting person and includes a power of attorney authorizing an attorney-in-fact to sign on his behalf.

Phibro Animal Health Corporation insider activity centers on BFI Co., LLC, an entity associated with President and CEO Jack Bendheim. On January 13, 2026, BFI sold 7,551 shares of Class A common stock at a weighted average price of $40.3154 under a Rule 10b5-1 trading plan. On January 14, 2026, BFI converted 20,000 shares of Class B common stock into 20,000 shares of Class A at a conversion price of $0, then sold 3,258 shares at a weighted average price of $40.4592 and 393 shares at $41.1375. On January 15, 2026, BFI sold an additional 2,932 shares at a weighted average price of $40.0233. Following these transactions, BFI indirectly holds 44,525 shares of Class A common stock and 19,941,034 shares of Class B common stock, while Jack Bendheim directly holds 16,840 shares of Class A common stock.